# AstraZeneca’s Symbicort approved in China as an anti-inflammatory reliever in mild asthma

- Link: https://www.directorstalkinterviews.com/astrazenecas-symbicort-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma/412955863
- Published: 2021-01-26T07:18:50+00:00
- Author: Amilia Stone

AstraZeneca’s _Symbicort Turbuhaler_ (budesonide/formoterol 160/4.5mcg) has been
approved in China as an anti-inflammatory reliever to be taken as-needed in response
to symptoms to achieve asthma control in patients with mild asthma aged 12 years
and older.

The approval by the National Medical Products Administration (NMPA) was based on
positive results from the SYGMA 1 and SYGMA 2 Phase III trials, published in _The_
_New England Journal of Medicine_, which evaluated the efficacy of _Symbicort Turbuhaler_
taken as-needed as an anti-inflammatory reliever compared with standard of care (
SoC) therapies in mild asthma. SoC included short-acting beta2-agonist (SABA) taken
as-needed or regular maintenance controller therapy (twice-daily budesonide, an 
inhaled corticosteroid (ICS)) plus SABA taken as-needed.^(1,2)

_Symbicort Turbuhaler_ is the first dual-combination therapy approved in China as
an anti-inflammatory reliever to treat mild asthma. It is already approved in China
for patients with moderate to severe asthma as an anti-inflammatory reliever plus
maintenance therapy, and as maintenance therapy only.

Asthma is a chronic, variable, inflammatory disease which can cause asthma attacks
and symptoms including breathlessness and wheezing.^(3) Asthma affects an estimated
46 million adults in China, including an estimated 34 million with mild asthma.^(
4,5)

> **Professor Xin Zhou, Vice President of the 10th China Thoracic Society and the
> respiratory discipline leader, Shanghai General Hospital, China, said: **“This
> approval aligns to the latest National Asthma Guidelines from the Chinese Thoracic
> Society as well as international recommendations from the Global Initiative for
> Asthma which recommend a low dose corticosteroid-formoterol combination therapy
> taken as-needed as the preferred reliever therapy in mild asthma. Now doctors 
> in China can prescribe _Symbicort Turbuhaler_ to reduce the impact of asthma on
> their patients with mild, moderate and severe disease.”

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: **“Everyone
> with asthma is at risk of an attack, regardless of their age, disease severity,
> adherence to treatment or level of control. This approval means people with mild
> asthma in China can now take _Symbicort Turbuhaler_ as an anti-inflammatory reliever
> to treat their symptoms and also to reduce the likelihood of an attack by treating
> the underlying inflammation in their airways. This approval builds on _Symbicort’s_
> established role in treating moderate to severe disease.”

The safety and tolerability data for _Symbicort Turbuhaler_ in the SYGMA trials 
were consistent with the known profile of the medicine.^(1,2)

_Symbicort _is a combination of an ICS that treats underlying inflammation and a
long-acting beta2-agonist (LABA) bronchodilator with a fast onset of action in a
single inhaler. _Symbicort Turbuhaler_ has been approved as an anti-inflammatory
reliever taken as-needed in mild asthma in 35 countries, and regulatory reviews 
are ongoing in additional countries.

**Symbicort**

_Symbicort_ (budesonide/formoterol) is the number one ICS/LABA combination therapy
in asthma and chronic obstructive pulmonary disease (COPD) in China. It is a combination
formulation containing budesonide, an ICS that treats underlying inflammation, and
formoterol, a LABA with a fast onset of action, in a single inhaler. _Symbicort_ was
launched in 2000 and is approved in approximately 120 countries to treat asthma 
and/or COPD either as _Symbicort Turbuhaler_ or _Symbicort_ pMDI (pressurised metered-
dose inhaler).

_Symbicort Turbuhaler_ is the first dual-combination therapy approved in China as
an anti-inflammatory reliever to treat mild asthma. It is already approved in China
for patients with moderate to severe asthma as an anti-inflammatory reliever plus
maintenance therapy (12 years and older) and as maintenance therapy only (six years
and older).

**AstraZeneca in Respiratory & Immunology**

Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key
growth driver for the Company.

Share on:
